

# Medical conditions in autism spectrum disorders

Patrick F. Bolton

Received: 4 April 2009 / Accepted: 2 June 2009 / Published online: 7 July 2009  
© Springer Science + Business Media, LLC 2009

**Abstract** Autism spectrum disorder (ASD) is a behaviourally defined syndrome where the etiology and pathophysiology is only partially understood. In a small proportion of children with the condition, a specific medical disorder is identified, but the causal significance in many instances is unclear. Currently, the medical conditions that are best established as probable causes of ASD include Fragile X syndrome, Tuberous Sclerosis and abnormalities of chromosome 15 involving the 15q11-13 region. Various other single gene mutations, genetic syndromes, chromosomal abnormalities and rare de novo copy number variants have been reported as being possibly implicated in etiology, as have several ante and post natal exposures and complications. However, in most instances the evidence base for an association with ASD is very limited and largely derives from case reports or findings from small, highly selected and uncontrolled case series. Not only therefore, is there uncertainty over whether the condition is associated, but the potential basis for the association is very poorly understood. In some cases the medical condition may be a consequence of autism or simply represent an associated feature deriving from an underlying shared etiology. Nevertheless, it is clear that in a growing proportion of individuals potentially causal medical conditions are being identified and clarification of their role in etio-pathogenesis is necessary. Indeed, investigations into the causal mechanisms underlying the association between conditions such as tuberous sclerosis, Fragile X and chromosome 15 abnormalities are beginning to cast light on the molecular and neurobiological pathways involved in the pathophysiology of ASD. It is evident

therefore, that much can be learnt from the study of probably causal medical disorders as they represent simpler and more tractable model systems in which to investigate causal mechanisms. Recent advances in genetics, molecular and systems biology and neuroscience now mean that there are unparalleled opportunities to test causal hypotheses and gain fundamental insights into the nature of autism and its development.

**Keywords** Autism · Genetics · Medical disorders · Epidemiology · Risk pathways

## Introduction

Ever since it was realized that autism was a result of a neurodevelopmental abnormality, there have been an increasing number of reports of various medical conditions in individuals with autism and autistic-like conditions. For the most part the early papers comprised case reports and small case series that described a wide variety of medical conditions including genetic disorders, chromosomal abnormalities and infectious diseases. In addition, various markers of abnormal brain development (e.g. minor and major congenital anomalies) and risk factors for brain damage (e.g. pregnancy and birth complications) were also described. In general the prevalence of these medical conditions in individuals with autism was quite low, so it was often unclear whether they represented a chance co-occurrence or a true association.

Over the last two decades changes and broadening of our diagnostic concepts [1–3] and improvements in the methods of case identification and diagnosis [4, 5] have led to the notion that autism is a prototypical form of ‘spectrum disorder’. Autism spectrum disorder (ASD) includes con-

---

P. F. Bolton (✉)  
The Social Genetic & Developmental Psychiatry Centre and The  
Department of Child and Adolescent Psychiatry,  
The Institute of Psychiatry, King’s College London,  
London, England  
e-mail: [patrick.bolton@kcl.ac.uk](mailto:patrick.bolton@kcl.ac.uk)

ditions such as Asperger's syndrome, atypical autism and 'other' pervasive developmental disorders (ICD-10). The prevalence of autism spectrum disorder in the UK is now thought to be in the order of 1% [6].

Parallel developments in medical diagnostics have also lead to improvements in the detection and diagnosis of medical conditions, so the prevalence of these conditions in individuals with ASD has also increased. Table 1 summarises the rates of medical conditions reported in a [7–11] number of population based studies of individuals with ASD. It can be anticipated that these prevalence figures will increase further, as the recent technical advances that have been made in the identification of submicroscopic chromosomal abnormalities (copy number variants [12]) are applied more routinely in the investigation of children with autism spectrum disorders. Currently, the evidence indicates that the conditions are more common in individuals with mental retardation / intellectual disabilities and those with atypical autism [13]. The findings raise the possibility of etiological heterogeneity.

Despite these advances, the aetiological significance of many medical conditions in individuals with ASD remains uncertain. Figure 1 outlines the main reasons why a medical condition may be identified in somebody with an autism spectrum disorder. Clearly, the first task is to determine whether the presence of the medical condition is a coincidental finding, or whether it derives from a true association. The possibility of chance co-occurrence can not be dismissed as a theoretical concern that is unlikely to be relevant. Instead it represents a real possibility for several reasons. Firstly, individuals with an ASD are more systematically and intensely investigated for medical conditions than individuals from the general population. Thus, a condition is more likely to be identified. Moreover, the true prevalence of the medical disorder in the general population is often not well specified, as the rarity of many conditions means that estimation of accurate prevalence figures would require the investigation of extremely large sized populations. The challenge is well illustrated by the


difficulty in obtaining accurate estimates of the prevalence of fragile X in the general population [14]. Taken in conjunction with the fact that many studies of medical conditions in ASD are uncontrolled, this is a potentially important limitation. Second, medical conditions in clinical populations will be over represented, because individuals with two or more conditions are more likely to come to medical attention—the so called Berkson bias [15, 16]. As such, studies of clinic series really do require data from comparison clinic populations for the results to be interpretable, unless of course the effect observed were so large that the null hypothesis would be implausible. In most examples this is not the case.

The most unbiased test for association is to undertake an epidemiologically designed case control study. In this context it would be best to test a population based sample of individuals with ASD and an appropriately matched control population for the medical condition under investigation. Conversely, it is also valuable to determine the prevalence of autism spectrum disorder in a population derived sample of individuals with the specified medical condition as well as an appropriately selected population based comparison group. These two sources of information can then be used to determine the presence and strength of any association between ASD and the medical condition. Clearly however, the rarity of some of the medical conditions that are potentially implicated (sometimes less than 1 in 1000 in the general population and less than 5% in ASD) as well as the relatively low prevalence of autism spectrum disorder in the general population means that very large samples would be required to establish whether a true association exists. In many cases, the costs of such a study would be prohibitive. Accordingly, data from carefully conducted case-control studies of clinic populations may be the only feasible strategy for initially demonstrating association.

In any case, the selection of the control group requires careful consideration. The choice partly depends on the design and aim of the study. Within the context of epidemiological studies, an age and sex matched general population sample would help determine if the two disorders are associated. In studies of a series of clinic cases, a decision has to be taken as to what other clinical population to choose as the comparison group. The choice primarily lies between a series of cases with another neuropsychiatric or neurodevelopmental disorder (e.g. ADHD or mental retardation / intellectual disability) or if the case series comprises a specific medical condition, some other medical disorder (e.g. Down syndrome). The exact choice will depend on the specific question being addressed. It is noteworthy in this regard that some studies have compared the frequency of medical condition in series of cases with autism spectrum disorder to the prevalence in

**Table 1** Medical conditions in autism spectrum disorder population samples

Study	Rate
Gillberg & Coleman (1996)	25%
Fombonne et al (1997)	10%
Skjeldal et al (1998)	8%
Barton & Volkmar (1998)	9.8%
Lauritsen et al (2002)	11.9%
Kielinen et al (2004)	12.3%
Oliveira et al (2007)	20%
Total	13.9%

**Fig. 1** Mechanisms of association

individuals with non autistic mental retardation / intellectual disability. Sometimes, if no difference in frequency has been observed, it has been concluded that there is no evidence for association between the medical condition and autism spectrum disorder. However, the only formal conclusion from studies of this kind is that the medical condition is not *specifically* associated with ASD, rather than the condition is not associated with ASD.

Apart from the sampling issues another methodological consideration concerns the assessment and diagnosis of autism spectrum disorder. In many studies the established semi standardised diagnostic tools currently in use were not available or utilised at the time of the study, so there is some uncertainty about the validity of diagnoses in some cases / case series. Moreover, the limited use of any semi standardised measures means that the details of the patterns

of impairments are not well characterised, so the extent and degree of homology in symptoms and signs of ASD remain unknown. The issue is well illustrated in the reports of the behavioural signs and symptoms founds in individuals with fetal alcohol syndrome Fetal alcohol [17–21], where detailed characterisation of the manifestations reveals that there are different features and profiles of deficits associated with the medical condition. Clearly therefore, careful assessment and characterisation is important in order to determine the degree to which there is specificity in symptomatology and signs.

Tables 2, 3, 4 and 5 summarises the evidence base for association between autism spectrum disorder and various medical conditions, according to the type of study design. The list of disorders reported is not exhaustive, but focuses on the conditions where evidence from a combination of sources

**Table 2** Medical conditions and autism spectrum disorder

Condition	Pop ASD	Pop Med	Case-control ASD	Case control Med	Case series ASD	Case series Med	Case report
<b>Obstetric complications</b>	x	x	x		x		x
Congenital Rubella					x	x	
Valproate Embryopathy						x	x
Neonatal Encephalopathy		x				x	x
<b>Congenital anomalies</b>	x		x		x	x	x
Ear infection	x				x		x
Malaria						x	
Herpes simplex						x	x
<b>Macrocephaly</b>	x	x	x		x		x
Bowel habit	x				x	x	x
<b>Infantile Epilepsy</b>	x	x	x	x	x	x	x
<b>Later onset Epilepsy</b>	x				x	x	x
Cerebral Malaria						x	
Thalidomide Embryopathy						x	

**Table 3** Genetic syndromes

Condition	Pop ASD	Pop Med	Case-control ASD	Case control Med	Case series ASD	Case series Med	Case report
<b>Tuberous Sclerosis</b>	x	x	x		x	x	x
<b>Fragile X Full</b>	x		x		x	x	x
<b>Pre</b>	x				x	x	x
Rett syndrome					x	x	x
Smith Lemli Opitz						x	x
Phenylketonuria						x	x
Neurofibromatosis 1	x		x		x	x	x
Myotonic Dystrophy							
DMPK						x	x
Sotos syndrome							
(NSD1)						x	x
Timothy syndrome						x	
Cornelia De Lange						x	
Cohen syndrome						x	

suggests a possible link. For recent reviews the reader should refer to Zafeiriou et al. (2007) and Abrahams and Geschwind (2008) [22, 23].

Even so, most findings still primarily stem from case reports or small uncontrolled case series, so a good deal of uncertainty remains as to whether the findings reflect chance co-occurrences. Where the evidence for association is fairly clear, the medical condition has been highlighted in the table in bold. Convincing evidence for an association exists for tuberous sclerosis [8, 24–29] Fragile X [30, 31, abnormalities in the chromosome 15q11-13 region [32–52], macrocephaly [53–57] minor congenital anomalies [58–60] and pre- / per-natal complications [61–74].

Even amongst these examples, the design and methodology of the studies entails one or other weakness so the findings can not be considered indisputably conclusive. In particular, most studies were not specifically set up to test for comorbidity between autism spectrum disorder and the specific medical condition. Rather, the finding comes from a secondary analysis of the data and the methods of assessment and diagnosis of the autism spectrum disorder

and / or the medical condition may not have been conducted as rigorously as would be desirable. Nevertheless, in the case of tuberous sclerosis and fragile X syndrome, it is clear that the evidence base is sufficiently strong to indicate that a true association is highly likely: the strength of the association, however, may not have been accurately estimated.

Having established that a true association likely exists, it is necessary to consider the possible basis for the association. The main mechanisms are outlined in Fig. 1. In most instances, the underlying risk mechanisms or pathway have not been fully elucidated, but for the purpose of illustration, some putative pathways can be postulated.

### Medical conditions as a consequence of autism spectrum disorder (ASD)

At first sight, it seems quite improbable that autism may be the cause of a medical condition, but Ileal lymphoid hyperplasia serves as a possible example of these mechanisms. Ileal

**Table 4** Single gene mutations / rare variants and autism spectrum disorder

Condition	Pop ASD	Pop Med	Case-control ASD	Case control Med	Case series ASD	Case series Med	Case report
Neurologin 4			x		x		x
Neurologin 3					x		x
Neurexin 1			X		x		x
CNTNAP2			X		x		x
PTEN					x		x
Reelin			X		x		
Shank3			x		x		x

**Table 5** Genomic disorders and autism spectrum disorder

Condition	Pop ASD	Pop Med	Case-control ASD	Case control Med	Case series ASD	Case series Med	Case report
2q37						x	x
7q11.3					x	x	x
<b>15q11-13</b>			<b>x</b>	<b>x</b>	<b>x</b>	<b>x</b>	<b>x</b>
15q11.2					x		
15q13.3					x		
16p11.2			x		x		x
16p13.1			x		x		x
17p11.2						x	
Trisomy 21					x	x	x
22q11.2					x	x	x
22q13.3					x	x	x
Xp22.3					x	x	
XXY						x	x
XO					x	x	x

lymphoid hyperplasia has been reported in small case series of children with ASD [75]. It is a condition that is also seen in children with constipation [76]. Children with autism sometimes have markedly unusual diets because of extreme food fads. It is therefore quite possible that the abnormal diet deriving from autistic food fads leads to constipation, which in turn leads to Ileal lymphoid hyperplasia. The issue requires investigation.

### Medical conditions arising from shared etiology

For some medical conditions, it seems highly likely that their association with ASD reflects the fact that there is some underlying shared risk factor that leads to the medical condition and the ASD. Examples where this mechanism is likely to underlie the association include macrocephaly, minor congenital anomalies and later onset epilepsy.

#### Macrocephaly

A significant minority of children with ASD develop macrocephaly. [53–57]. In a few individuals with ASD and macrocephaly, mutations in PTEN and NSD1 have been identified [77–82]. These mutations give rise to Cowden and Soto's syndromes respectively and both conditions are associated with macrocephaly. Soto's syndrome has previously been reported in individuals with ASD [83].

The limited available evidence also suggests that the macrocephaly seen in cases of ASD is familial [54], raising the possibility of shared familial liability for macrocephaly and autism spectrum disorder and the broader autism phenotype, but this possibility has not yet systematically examined.

#### Minor congenital anomalies

Several studies have shown an association between minor congenital anomalies and ASD [58–60]. The current evidence indicates that the presence of minor congenital anomalies indexes a reduced likelihood of familial recurrence of ASD [84]. Recent findings also indicate that *de novo* copy number variants are associated with ASD [85–90] as well as minor congenital anomalies and mental retardation [91, 92]. Taken together, the findings suggest that the presence of minor congenital anomalies may index *de novo* copy number variants and possibly other non familial risk factors for ASD.

#### Epilepsy

Epilepsy occurs in around 20–30% of individuals with autism and the age of onset tends to be in late childhood or adolescence [93–97]. The basis for the association is however poorly understood. There is evidence that the familial liabilities to epilepsy and autism spectrum disorder are correlated (at least in the group with onset in later childhood or beyond), indicating shared familial risks. The picture may be different however in the group with early onset epilepsy (see below).

### Medical conditions as correlated risk factors

In some instances, the risk pathway may be more complex. For example, there may be a shared aetiology underlying the association, but in addition there may be a path between the medical condition and ASD, modifying or exacerbating the manifestations of the behavioural syn-

drome. Infantile epilepsy constitutes a potential example [28, 98–103]. In these conditions, the etio-pathogenesis of the epilepsy is poorly understood, but markers of the presence of an underlying brain abnormality have been reported to index an increased risk for ASD. This suggests that there may be a shared, poorly specified, underlying cause for ASD and epilepsy. In addition however, there is some evidence to suggest that epilepsy in this early sensitive period of development may also be detrimental to brain development and the instantiation of social cognitive representations, thereby predisposing to a risk for ASD or exacerbating the risk stemming from the underlying brain abnormality [28, 103].

Another example concerns pre and perinatal complications. A number of studies have reported an association between ASD and pre and perinatal complications [61–74]. However, the current evidence suggests that these putative environmental risk factors occurring during pregnancy and birth may in fact represent a form person-environment correlation. That is that the genetic factors associated with ASD lead the individuals to being more likely to experience certain environmental events. This may apply to the association with pre and peri - natal problems [71, 104]. Nevertheless, it is possible that these experiences may modify or exacerbate the manifestations of ASD.

### Medical conditions as a cause of ASD

In addition to the better known Mendelian genetic conditions (e.g. Smith Lemli Opitz [105–107]; Neurofibromatosis 1 [29, 108–113]; Rett syndrome [114–117], there are a growing number of genomic disorders and single gene mutations / rare variants that are being identified in individuals with ASD. These include mutations in Neuro-ligin 3+4 / neuroligin 1 [32, 118–124]; Shank3 [89, 125, 126]; Contactin associated protein-like 2 [127]; Reelin [128] and PTEN [77, 79]


In addition, ASD has been associated with various microscopic chromosomal abnormalities involving the 15q11-13 region [33–39, 41–47, 49–52, 129–135]; 22q11.2 [136–139] and submicroscopic de novo copy number variants including those that involve [85, 88, 90, 140–144] various regions (see Table 5). Intriguingly, there are a number of reports suggesting that both microdeletions and microduplications may predispose to ASD at some loci, suggesting that the genes involved are dosage sensitive and that both up and down regulation may perturb the pathway underlying the risk for ASD [145–147].

There are very good reasons to think that when a genetic condition is confirmed to be associated with ASD, that the genetic disorder is the cause of the ASD. However, an important caveat needs to be borne in mind. That is that the causal factors leading to ASD may also lead to the genetic

condition. Although this is highly unlikely in many cases, the mechanisms could plausibly underlie the reported association between genomic disorders (e.g. copy number variants — CNV's) and ASD. For example, some factor that leads to ASD could also give rise to chromosomal instability and a propensity to develop CNV's. The current data do not suggest that this is likely to be the case, but the issue needs further investigation.

### Risk pathways

For conditions that are established as being probably causal, questions arise about the nature of the risk mechanisms underlying the association. Figure 2 illustrates the potential risk pathways in schematic form. With recent developments in network and systems biology, much richer models of causal pathways have been elaborated [148, 149]. Thus, it is now appreciated that the genetic risk factors ( $G_{1-n}$ ) interact with the entire genome to create a disease genome ( $D_{1-n}$ ), which also interacts with environmental risk factors ( $E_{1-n}$ ) to produce intermediate phenotypes ( $I_{1-n}$ ) and pathophysiological states that finally lead to the emergence of disease phenotypes ( $P_{1-n}$ ). This model can be applied to complex disorders and with simplification (reductions in  $n$ ) to simpler single gene



**Fig. 2** Interacting pathogenic networks and pathways



disorders etc. According to this model therefore, the association between a medical condition and ASD could derive from shared genetic risk, overlap in the associated disease genome, shared environmental risks, overlapping intermediate phenotypes (i.e. neurobiological and cognitive risks), shared pathophysiological states and similar or partially overlapping phenotypic manifestations. The task therefore is to map the networks of genetic and neurobiological risks leading to ASD in specific medical conditions and determine how this relates to the networks and paths identified in the more complex, ‘idiopathic’ form of ASD. It should be noted that for almost all the known probably causal medical conditions so far identified, ASD is the outcome in only a subset of cases. For example, about 50% of individuals with tuberous sclerosis do not develop an ASD [28, 40] and similarly around 70–80% of cases of fragile X do not develop an ASD [31]. This means that studies of individuals with specific medical disorders can throw light on the risk pathways leading to ASD. Indeed, mapping the risk mechanisms and paths in simpler and often rather better understood model systems such as tuberous sclerosis and fragile X and developing a full model of the risk and developmental processes involved would be invaluable for the research field.

### Mapping perturbations in gene networks and pathways

Some progress has already been made in clarifying the nature of the risk processes involved in some of the medical conditions associated with ASD. For example, it seems that the risk for ASD in tuberous sclerosis is partly dependent on whether the TSC1 or TSC2 gene is mutated [150, 151]. There is also some suggestion that the disease genome expression patterns may be associated with an ASD outcome in tuberous sclerosis. Likewise, the evidence indicates that the risk for ASD in fragile X syndrome is dependent on the presence of the full or pre-mutation [31] and that the risk for ASD deriving from abnormalities of chromosome 15 is dependent on the number and parental origin of the abnormality, with a high risk in individuals with more copies of the abnormality, especially if these are maternally derived [43, 134].

To date the most systematic attempt to map disease gene networks that underlie the risk for ASD has been undertaken by Nishimura and colleague. They studied gene expression profiles in lymphoblastoid cell lines established from individuals with ASD and the fragile X syndrome as well as individuals with ASD and maternally inherited interstitial duplication of 15q11-13. They found not only that there were distinct expression profiles associated with each genetic condition, but also that there were dysregulated expression profiles that were common to both genetic condition and that overlapped with the expression profile

seen in cases of idiopathic autism. These investigations have implicated dysregulation of the Janus Kinase and Microtubule interacting protein 1 (JAKMIP1) gene and the G Protein-coupled receptor 155 (GPR155) gene as markers for autism spectrum disorder [152]. Taken together these data indicate that dysregulation of specific genes within networks mark perturbations in the final causal pathway leading to autism spectrum disorder and the broader phenotype of autism. Clearly, there remains much more to be done, but it is evident that the potential exists to use these approaches to map the dysregulated pathways in detail.

### Mapping perturbations in neurobiological networks

Of course, there is a parallel need to map the nature of the perturbations in the development of neurobiological systems that underlie the risk for ASD in individuals with associated medical disorders. Here again, some, albeit limited, progress has been made in identifying neuroanatomical and neurophysiological correlates of outcome. For example, in tuberous sclerosis there is some evidence to suggest that the number and location of cortical tubers may index the risk for ASD [28]. Similarly, there are indications that the extent and location of brain changes in individuals with fragile X syndrome are associated with the fragile x mental retardation protein levels and the degree of cognitive impairment and autistic behaviour. The research in this area is in its infancy, but there is clearly much more that can potentially be learnt. Similar considerations apply to the mapping of putative intermediate cognitive phenotypes, where some work has also started to help determine which cognitive processes are key in the pathway to the behavioural syndrome, but as yet the map is just beginning to be outlined.

### The selection of disorders and focus of investigation

It is evident that different disorders provide different windows onto the potential risk mechanisms that give rise to autism spectrum disorder. For example, the study of genetic conditions that result from mutations in genes coding for transcription factors (e.g. fragile X) or complex genomic disorders provide special insights into the nature of the disease genome associated with ASD. However, because these conditions are likely to give rise to widespread effects on the gene networks and because the genetic effects are also likely to be pleiotropic, the extent to which these conditions can be used to map the neurobiological systems that underlie ASD is likely to be limited. Other medical condition may be more informative about the neurobiological basis of the disorder, so for example investigation of individuals with neurexin 1, neuroligin 3+4 and Shank 3 mutations would

help map the effects of disruptions to synaptic development and function. Similarly, the stochastic nature of the second hit events that give rise to the brain abnormalities seen in tuberous sclerosis mean that this model has special potential in mapping which brain systems are involved in creating a risk for ASD and testing theories about whether single or multiple primary hits in social brain or mirror neuron networks underlie the risk for ASD. The single deficit hypothesis postulates that some single underlying neurobiological abnormality may give rise to autism by setting in motion a cascade of developmental events that ultimately leads to autism spectrum disorder. The multiple primary deficit model postulates that ASD is the result of several separate neurobiological abnormalities (perhaps arising from the pleiotropic effects of genes) each giving rise to specific components of the cognitive / behavioural phenotype.

### Cross disorder comparisons

Further insights may be gained from comparing cases with different medical conditions according to whether they have ASD. Comparisons of this kind would help determine which conditions are necessary and sufficient for the emergence of ASD. As yet almost no work of this kind has been undertaken, but opportunity clearly exists and holds considerable promise.

### High risk designs and developmental processes

Medical conditions that are identified and diagnosed early in infancy can also provides an opportunity to study the developmental pathways leading to ASD and the sequence of events that unfold as the developmental cascade progresses [28, 103, 153]. Insights into these processes may help identify targets for early therapeutic intervention, both in individuals with medical conditions that carry a high risk for ASD as well as in cases at risk for idiopathic ASD.

### Testing phenotypic models

Another potential value of investigating individuals with medical disorders that carry a risk for ASD is to test models of the architecture of the phenotype and determine the extent to which the phenotype can be dimensionalized and/or fractionated. The notion that ASD is not a cohesive, unitary phenotype has been raised by recent twin study findings that propose that the phenotype comprises several dimensions (social, communication, repetitive behaviours) each with their own genetic underpinnings, as well as shared genetic risks [154, 155]. The findings from inves-

tigations of individuals with Fragile X syndrome [156–160], lend support to the notion that the phenotype can be dimensionalized and that ASD may be at the extreme end of a quasi normally distributed set of traits, but the extent to which this also applies to the phenotypic manifestations seen in other disorder (e.g. tuberous sclerosis) is unclear. Similarly, it is not know whether the phenotype fractionates in these conditions and if so what risk factors underlie each component of the compound phenotype.

### Conclusions

An increasing number of medical conditions are being identified in individuals with ASD and studies are starting to identify the conditions that probably play a causal role in etio-pathogenesis. Moreover, it is now appreciated that rather just representing rare phenomena that should be excluded from studies of ASD, that research aimed at understanding why these conditions carry a risk for ASD can cast light on the key risk processes that lead to ASD. The investigation of these simpler and potentially more tractable model systems is in its infancy but it is evident that it is a fertile area of investigation that can provide important insights on developmental mechanisms and risk processes. In addition, the study of these conditions can help answer current questions about the architecture of the phenotype.

**Acknowledgements** This research was supported by the UK NIHR Biomedical Research Centre for Mental Health at the Institute of Psychiatry, Kings College London and The South London and Maudsley NHS Foundation Trust.

### References

1. Bailey A, et al. Autism as a strongly genetic disorder: evidence from a British twin study. *Psychol-Med*. 1995;25(1):63–77. issn: 0033-2917.
2. Bolton P, et al. A case-control family history study of autism. *J Child Psychol Psychiatry*. 1994;35:877–900.
3. Piven J, Palmer P. Psychiatric disorder and the broad autism phenotype: evidence from a family study of multiple-incidence autism families. *Am J Psychiatry*. 1999;156(4):557–63.
4. Lord C, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord*. 2000;30(3):205–23.
5. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord*. 1994;24(5):659–85.
6. Baird G, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). *Lancet*. 2006;368(9531):210–5.
7. Barton M, Volkmar F. How commonly are known medical conditions associated with autism? *J Autism Dev Disord*. 1998;28(4):273–8.



8. Kielinen M, et al. Associated medical disorders and disabilities in children with autistic disorder: a population-based study. *Autism*. 2004;8(1):49–60.
9. Lauritsen M, et al. Infantile autism and associated autosomal chromosome abnormalities: a register-based study and a literature survey. *J Child Psychol Psychiatry*. 1999;40(3):335–45.
10. Oliveira G, et al. Epidemiology of autism spectrum disorder in Portugal: prevalence, clinical characterization, and medical conditions. *Dev Med Child Neurol*. 2007;49(10):726–33.
11. Sponheim E. Changing criteria of autistic disorders: a comparison of the ICD-10 research criteria and DSM-IV with DSM-III-R, CARS, and ABC. *J-Autism-Dev-Disord*. 1996;26(5):513–25. issn: 0162-3257.
12. Miller DT, Shen Y, Wu BL. Oligonucleotide microarrays for clinical diagnosis of copy number variation. *Curr Protoc Hum Genet*. 2008;Chapter 8: p. Unit 8 12.
13. Rutter M, et al. Autism and known medical conditions: myth and substance. *J Child Psychol Psychiatry*. 1994;35:311–22.
14. Hagerman PJ. The fragile X prevalence paradox. *J Med Genet*. 2008;45(8):498–9.
15. Conn HO, Snyder N, Atterbury CE. The Berkson bias in action. *Yale J Biol Med*. 1979;52(1):141–7.
16. Feinstein AR, Walter SD, Horwitz RI. An analysis of Berkson's bias in case-control studies. *J Chronic Dis*. 1986;39(7):495–504.
17. Bishop S, Gahagan S, Lord C. Re-examining the core features of autism: a comparison of autism spectrum disorder and fetal alcohol spectrum disorder. *J Child Psychol Psychiatry*. 2007;48(11):1111–21.
18. Klug MG, et al. A comparison of the effects of parental risk markers on pre- and perinatal variables in multiple patient cohorts with fetal alcohol syndrome, autism, Tourette syndrome, and sudden infant death syndrome: an enviromic analysis. *Neurotoxicol Teratol*. 2003;25(6):707–17.
19. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. *Am J Psychiatry*. 2005;162(6):1133–41.
20. Harris SR, MacKay LL, Osborn JA. Autistic behaviors in offspring of mothers abusing alcohol and other drugs: a series of case reports. *Alcohol Clin Exp Res*. 1995;19(3):660–5. issn: 0145-6008.
21. Nanson JL. Autism in fetal alcohol syndrome: a report of six cases. *Alcohol Clin Exp Res*. 1992;16(3):558–65. issn: 0145-6008.
22. Zafeiriou DI, Ververi A, Vargiami E. Childhood autism and associated comorbidities. *Brain Dev*. 2007;29(5):257–72.
23. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. *Nat Rev Genet*. 2008;9(5):341–55.
24. Curatolo P, Cusmai R. Autism and infantile spasms in children with tuberous sclerosis [letter]. *Dev Med Child Neurol*. 1987;29(4):551.
25. Gillberg IC, Gillberg C, Ahlsen G. Autistic behaviour and attention deficits in tuberous sclerosis: A population-based study. *Dev Med Child Neurol*. 1994;36:50–56.
26. Hunt A, Shepherd C. A prevalence study of autism in tuberous sclerosis. *J Autism Dev Disord*. 1993;23:323–39.
27. Smalley S, Tanguay P, Smith M. Association of Autism and Tuberous Sclerosis. *Am J Hum Genet*. 1991;49(4):164–164.
28. Bolton PF, et al. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. *Brain*. 2002;125(Pt 6):1247–55.
29. Fombonne E, et al. Autism and associated medical disorders in a French epidemiological survey. *J Am Acad Child Adolesc Psychiatry*. 1997;36(11):1561–9.
30. Bailey A, et al. Prevalence of the fragile X anomaly amongst autistic twins and singletons. *J Child Psychol Psychiatry Allied Discip*. 1993;34(5):673–88.
31. Clifford S, et al. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. *J Autism Dev Disord*. 2007;37(4):738–47.
32. Kim HG, et al. Disruption of neurexin 1 associated with autism spectrum disorder. *Am J Hum Genet*. 2008;82(1):199–207.
33. Ouldim K, et al. Tetrasomy 15q11–q13 Diagnosed by FISH in a Patient with Autistic Disorder. *J Biomed Biotechnol*. 2007;2007(3):61538.
34. Dennis NR, et al. Clinical findings in 33 subjects with large supernumerary marker(15) chromosomes and 3 subjects with triplication of 15q11–q13. *Am J Med Genet*. 2006;140(5):434–41.
35. Koochek M, et al. 15q duplication associated with autism in a multiplex family with a familial cryptic translocation t(14;15)(q11.2;q13.3) detected using array-CGH. *Clin Genet*. 2006;69(2):124–34.
36. Sahoo T, et al. Array-based comparative genomic hybridization analysis of recurrent chromosome 15q rearrangements. *Am J Med Genet*. 2005;139A(2):106–13.
37. Battaglia A. The inv dup(15) or idic(15) syndrome: a clinically recognisable neurogenetic disorder. *Brain Dev*. 2005;27(5):365–9.
38. Dykens EM, Sutcliffe JS, Levitt P. Autism and 15q11–q13 disorders: behavioral, genetic, and pathophysiological issues. *Ment Retard Dev Disabil Res Rev*. 2004;10(4):284–91.
39. Simic M, Turk J. Autistic spectrum disorder associated with partial duplication of chromosome 15; three case reports. *Eur Child Adolesc Psychiatry*. 2004;13(6):389–93.
40. Bolton PF. Neuroepileptic correlates of autistic symptomatology in tuberous sclerosis. *Ment Retard Dev Disabil Res Rev*. 2004;10(2):126–31.
41. Thomas JA, et al. Genetic and clinical characterization of patients with an interstitial duplication 15q11–q13, emphasizing behavioral phenotype and response to treatment. *Am J Med Genet*. 2003;119A(2):111–20.
42. Silva AE, et al. Tetrasomy 15q11–q13 identified by fluorescence in situ hybridization in a patient with autistic disorder. *Arq Neuropsiquiatr*. 2002;60(2-A):290–4.
43. Bolton PF, et al. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. *Am J Med Genet*. 2001;105(8):675–85.
44. Wolpert CM, et al. Three probands with autistic disorder and isodicentric chromosome 15. *Am J Med Genet*. 2000;96(3):365–72.
45. Wolpert C, et al. Autistic symptoms among children and young adults with isodicentric chromosome 15. *Am J Med Genet*. 2000;96(1):128–9.
46. Rineer S, Finucane B, Simon EW. Autistic symptoms among children and young adults with isodicentric chromosome 15. *Am J Med Genet*. 1998;81(5):428–33.
47. Repetto GM, et al. Interstitial duplications of chromosome region 15q11q13: clinical and molecular characterization. *Am J Med Genet*. 1998;79(2):82–9.
48. Sabry MA, Farag TI. Chromosome 15q11–13 region and the autistic disorder [letter]. *J Intellect Disabil Res*. 1998;42(Pt 3):259.
49. Schroer RJ, et al. Autism and maternally derived aberrations of chromosome 15q. *Am J Med Genet*. 1998;76(4):327–36.
50. Cook EH Jr, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. *Am J Hum Genet*. 1997;60(4):928–34. issn: 0002-9297.
51. Martinsson T, et al. Maternal origin of inv dup(15) chromosomes in infantile autism. *Eur Child Adolesc Psychiatry*. 1996;5(4):185–92. issn: 1018-8827.
52. Bunday S, et al. Duplication of the 15q11–13 region in a patient with autism, epilepsy and ataxia. *Dev Med Child Neurol*. 1994;36(8):736–42.
53. Bolton PF, et al. Association between idiopathic infantile macrocephaly and autism spectrum disorders. *Lancet*. 2001;358(9283):726–7.

54. Lainhart JE, et al. Head circumference and height in autism: a study by the Collaborative Program of Excellence in Autism. *Am J Med Genet*. 2006;140(21):2257–74.
55. Woodhouse W, et al. Head circumference in autism and other pervasive developmental disorders. *J Child Psychol Psychiatry*. 1996;37(6):665–71.
56. Courchesne E, et al. Mapping early brain development in autism. *Neuron*. 2007;56(2):399–413.
57. Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. *Biol Psychiatry*. 2005;58(1):1–9.
58. Tripi G, et al. Minor physical anomalies in children with autism spectrum disorder. *Early Hum Dev*. 2008;84(4):217–23.
59. Walker HA. Incidence of minor physical anomaly in autism. *J Autism-Child-Schizophr*. 1977;7(2):165–76. issn: 0021-9185.
60. Miles JH, et al. Development and validation of a measure of dysmorphology: useful for autism subgroup classification. *Am J Med Genet*. 2008;146A(9):1101–16.
61. Kolevzon A, Gross R, Reichenberg A. Prenatal and perinatal risk factors for autism: a review and integration of findings. *Arch Pediatr Adolesc Med*. 2007;161(4):326–33.
62. Brimacombe M, Ming X, Lamendola M. Prenatal and birth complications in autism. *Matern Child Health J*. 2007;11(1):73–9.
63. Maimburg RD, Vaeth M. Perinatal risk factors and infantile autism. *Acta Psychiatr Scand*. 2006;114(4):257–64.
64. Stein D, et al. Obstetric complications in individuals diagnosed with autism and in healthy controls. *Compr Psychiatry*. 2006;47(1):69–75.
65. Sugie Y, et al. Neonatal factors in infants with Autistic Disorder and typically developing infants. *Autism*. 2005;9(5):487–94.
66. Glasson EJ, et al. Perinatal factors and the development of autism: a population study. *Arch Gen Psychiatry*. 2004;61(6):618–27.
67. Wilkerson DS, et al. Perinatal complications as predictors of infantile autism. *Int J Neurosci*. 2002;112(9):1085–98.
68. Hultman CM, Sparen P, Cnattingius S. Perinatal risk factors for infantile autism. *Epidemiology*. 2002;13(4):417–23.
69. Zwaigenbaum L, et al. Pregnancy and birth complications in autism and liability to the broader autism phenotype. *J Am Acad Child Adolesc Psychiatry*. 2002;41(5):572–9.
70. Juul-Dam N, Townsend J, Courchesne E. Prenatal, perinatal, and neonatal factors in autism, pervasive developmental disorder-not otherwise specified, and the general population. *Pediatrics*. 2001;107(4):E63.
71. Bolton PF, et al. Obstetric complications in autism: consequences or causes of the condition? *J-Am-Acad-Child-Adolesc-Psychiatry*. 1997;36(2):272–81. issn: 0890-8567.
72. Cryan E, et al. A case-control study of obstetric complications and later autistic disorder. *J-Autism-Dev-Disord*. 1996;26(4):453–60. issn: 0162-3257.
73. Deykin EY, MacMahon B. Pregnancy, delivery, and neonatal complications among autistic children. *Am-J-Dis-Child*. 1980;134(9):860–4. issn: 0002-922x.
74. Finegan JA, Quarrington B. Pre-, peri-, and neonatal factors and infantile autism. *J-Child-Psychol-Psychiatry*. 1979;20(2):119–28. issn: 0021-9630.
75. Wakefield AJ, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet*. 1998;351(9103):637–41.
76. MacDonald TT, Domizio P. Autistic enterocolitis; is it a histopathological entity? *Histopathology*. 2007;50(3):371–9. discussion 380–4.
77. Buxbaum JD, et al. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. *Am J Med Genet B Neuropsychiatr Genet*. 2007;144B(4):484–91.
78. Buxbaum JD, et al. Mutation analysis of the NSD1 gene in patients with autism spectrum disorders and macrocephaly. *BMC Med Genet*. 2007;8:68.
79. Goffin A, et al. PTEN mutation in a family with Cowden syndrome and autism. *Am J Med Genet*. 2001;105(6):521–4.
80. Herman GE, et al. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. *Am J Med Genet*. 2007;143(6):589–93.
81. Orrico A, et al. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. *Clin Genet*. 2009;75(2):195–8.
82. Varga EA, et al. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. *Genet Med*. 2009;11(2):111–7.
83. Morrow JD, Whitman BY, Accardo PJ. Autistic disorder in Sotos syndrome: a case report. *Eur J Pediatr*. 1990;149(8):567–9. issn: 0340-6199.
84. Pickles A, et al. Variable expression of the autism broader phenotype: findings from extended pedigrees. *J Child Psychol Psychiatry*. 2000;41(4):491–502.
85. Christian SL, et al. Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. *Biol Psychiatry*. 2008;63(12):1111–7.
86. Hogart A, et al. The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. *Neurobiol Dis*;2008.
87. Kakinuma H, Sato H. Copy-number variations associated with autism spectrum disorder. *Pharmacogenomics*. 2008;9(8):1143–54.
88. Marshall CR, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet*. 2008;82(2):477–88.
89. Moessner R, et al. Contribution of SHANK3 mutations to autism spectrum disorder. *Am J Hum Genet*. 2007;81(6):1289–97.
90. Sebat J, et al. Strong association of de novo copy number mutations with autism. *Science*. 2007;316(5823):445–9.
91. de Ravel TJ, et al. Molecular karyotyping of patients with MCA/MR: the blurred boundary between normal and pathogenic variation. *Cytogenet Genome Res*. 2006;115(3–4):225–30.
92. Edelmann L, Hirschhorn K. Clinical utility of array CGH for the detection of chromosomal imbalances associated with mental retardation and multiple congenital anomalies. *Ann N Y Acad Sci*. 2009;1151:157–66.
93. Tuchman R, Rapin I. Epilepsy in autism. *Lancet Neurol*. 2002;1(6):352–8.
94. Howlin P, et al. Adult outcome for children with autism. *J Child Psychol Psychiatry*. 2004;45(2):212–29.
95. Amiet C, et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. *Biol Psychiatry*. 2008;64(7):577–82.
96. Hara H. Autism and epilepsy: a retrospective follow-up study. *Brain Dev*. 2007;29(8):486–90.
97. Canitano R. Epilepsy in autism spectrum disorders. *Eur Child Adolesc Psychiatry*. 2007;16(1):61–6.
98. Saemundsen E, Ludvigsson P, Rafnsson V. Autism spectrum disorders in children with a history of infantile spasms: a population-based study. *J Child Neurol*. 2007;22(9):1102–7.
99. Saemundsen E, et al. Autism spectrum disorders in children with seizures in the first year of life - a population-based study. *Epilepsia*. 2007;48(9):1724–30.
100. Deonna T, et al. Autistic regression associated with seizure onset in an infant with tuberous sclerosis. *Dev Med Child Neurol*. 2007;49(4):320.
101. Kayaalp L, et al. EEG abnormalities in West syndrome: correlation with the emergence of autistic features. *Brain Dev*. 2007;29(6):336–45.
102. Deonna T, Roulet E. Autistic spectrum disorder: evaluating a possible contributing or causal role of epilepsy. *Epilepsia*. 2006;47(Suppl 2):79–82.
103. Humphrey A, et al. Autistic regression associated with seizure onset in an infant with tuberous sclerosis. *Dev Med Child Neurol*. 2006;48(7):609–11.

104. Deb S, et al. A comparison of obstetric and neonatal complications between children with autistic disorder and their siblings. *J-Intellect-Disabil-Res.* 1997;41(Pt 1):81–6. issn: 0964-2633.
105. Bukelis I, et al. Smith-Lemli-Opitz syndrome and autism spectrum disorder. *Am J Psychiatry.* 2007;164(11):1655–61.
106. Tierney E, et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. *Am J Med Genet B Neuropsychiatr Genet.* 2006;141B(6):666–8.
107. Tierney E, et al. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. *Am J Med Genet.* 2001;98(2):191–200.
108. Martin I, et al. Transmission disequilibrium study of an oligodendrocyte and myelin glycoprotein gene allele in 431 families with an autistic proband. *Neurosci Res.* 2007;59(4):426–30.
109. Mbarek O, et al. Association study of the NF1 gene and autistic disorder. *Am J Med Genet.* 1999;88(6):729–32.
110. Marui T, et al. Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population. *Am J Med Genet B Neuropsychiatr Genet.* 2004;131B(1):43–7.
111. Williams PG, Hersh JH. Brief report: the association of neurofibromatosis type 1 and autism. *J Autism Dev Disord.* 1998;28(6):567–71.
112. Mouridsen SE, et al. Neurofibromatosis in infantile autism and other types of childhood psychoses. *Acta Paedopsychiatr.* 1992;55(1):15–8.
113. Gillberg C. Infantile autism and other childhood psychoses in a Swedish urban region. Epidemiological aspects. *J-Child-Psychol-Psychiatry.* 1984;25(1):35–43. issn: 0021-9630.
114. Loat CS, et al. Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism. *Genes Brain Behav.* 2008;7(7):754–60.
115. Matson JL, Dempsey T, Wilkins J. Rett syndrome in adults with severe intellectual disability: exploration of behavioral characteristics. *Eur Psychiatry.* 2008;23(6):460–5.
116. Mount RH, et al. Features of autism in Rett syndrome and severe mental retardation. *J Autism Dev Disord.* 2003;33(4):435–42.
117. Mount RH, et al. Towards a behavioral phenotype for Rett syndrome. *Am J Ment Retard.* 2003;108(1):1–12.
118. Durand CM, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat Genet.* 2007;39(1):25–7.
119. Jamain S, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat Genet.* 2003;34(1):27–9.
120. Yan J, et al. Neurexin 1alpha structural variants associated with autism. *Neurosci Lett.* 2008;438(3):368–70.
121. Levinson JN, El-Husseini A. A crystal-clear interaction: relating neuroligin/neurexin complex structure to function at the synapse. *Neuron.* 2007;56(6):937–9.
122. Chen X, et al. Structural basis for synaptic adhesion mediated by neuroligin-neurexin interactions. *Nat Struct Mol Biol.* 2008;15(1):50–6.
123. Feng J, et al. High frequency of neurexin 1beta signal peptide structural variants in patients with autism. *Neurosci Lett.* 2006;409(1):10–3.
124. Lise MF, El-Husseini A. The neuroligin and neurexin families: from structure to function at the synapse. *Cell Mol Life Sci.* 2006;63(16):1833–49.
125. Gauthier J, et al. Novel de novo SHANK3 mutation in autistic patients. *Am J Med Genet B Neuropsychiatr Genet.* 2009;150B(3):421–4.
126. Phelan MC. Deletion 22q13.3 syndrome. *Orphanet J Rare Dis.* 2008;3:14.
127. Bakkaloglu B, et al. Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. *Am J Hum Genet.* 2008;82(1):165–73.
128. Bonora E, et al. Analysis of reelin as a candidate gene for autism. *Mol Psychiatry.* 2003;8(10):885–92.
129. Kato C, et al. Association study of the 15q11–q13 maternal expression domain in Japanese autistic patients. *Am J Med Genet B Neuropsychiatr Genet.* 2008;147B(7):1008–12.
130. Weiss LA, et al. Association between microdeletion and microduplication at 16p11.2 and autism. *N Engl J Med.* 2008;358(7):667–75.
131. Bolton PF, et al. Chromosome 15q11–13 abnormalities and other medical conditions in individuals with autism spectrum disorders. *Psychiatr Genet.* 2004;14(3):131–7.
132. Sabry MA, Farag TI. Chromosome 15q11-13 region and the autistic disorder. *J Intellect Disabil Res.* 1998;42(Pt 3):259.
133. Veltman MW, et al. Prader-Willi syndrome—a study comparing deletion and uniparental disomy cases with reference to autism spectrum disorders. *Eur Child Adolesc Psychiatry.* 2004;13(1):42–50.
134. Milner KM, et al. Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. *J Child Psychol Psychiatry.* 2005;46(10):1089–96.
135. Sahoo T, et al. Microarray based comparative genomic hybridization testing in deletion bearing patients with Angelman syndrome: genotype-phenotype correlations. *J Med Genet.* 2006;43(6):512–6.
136. Kates WR, et al. Comparing phenotypes in patients with idiopathic autism to patients with velocardiofacial syndrome (22q11 DS) with and without autism. *Am J Med Genet.* 2007;143A(22):2642–50.
137. Mukaddes NM, Herguner S. Autistic disorder and 22q11.2 duplication. *World J Biol Psychiatry.* 2007;8(2):127–30.
138. Antshel KM, et al. Autistic spectrum disorders in velo-cardio facial syndrome (22q11.2 deletion). *J Autism Dev Disord.* 2007;37(9):1776–86.
139. Vorstman JA, et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. *J Am Acad Child Adolesc Psychiatry.* 2006;45(9):1104–13.
140. Bremer A, et al. Screening for copy number alterations in loci associated with autism spectrum disorders by two-color multiplex ligation-dependent probe amplification. *Am J Med Genet B Neuropsychiatr Genet.* 2009.
141. Cusco I, et al. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. *Hum Mol Genet.* 2009.
142. Szatmari P, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. *Nat Genet.* 2007;39(3):319–28.
143. Stefansson H, et al. Large recurrent microdeletions associated with schizophrenia. *Nature.* 2008;455(7210):232–6.
144. Roohi J, et al. Disruption of contactin 4 in three subjects with autism spectrum disorder. *J Med Genet.* 2009;46(3):176–82.
145. Van der Aa N, et al. Fourteen new cases contribute to the characterization of the 7q11.23 microduplication syndrome. *Eur J Med Genet.* 2009;52(2–3):94–100.
146. Potocki L, et al. Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. *Am J Hum Genet.* 2007;80(4):633–49.
147. Samaco RC, et al. A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. *Hum Mol Genet.* 2008;17(12):1718–27.
148. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. *Mol Syst Biol.* 2007;3:124.
149. Goh KI, et al. The human disease network. *Proc Natl Acad Sci U S A.* 2007;104(21):8685–90.
150. Lewis JC, et al. Genotype and psychological phenotype in tuberous sclerosis. *J Med Genet.* 2004;41(3):203–7.
151. Barrett S, et al. An autosomal genomic screen for autism. Collaborative linkage study of autism. *Am J Med Genet.* 1999;88(6):609–15.

152. Nishimura Y, et al. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. *Hum Mol Genet.* 2007;16(14):1682–98.
153. Humphrey A, et al. A prospective longitudinal study of early cognitive development in tuberous sclerosis-a clinic based study. *Eur Child Adolesc Psychiatry.* 2004;13(3):159–65.
154. Ronald A, et al. Genetic heterogeneity between the three components of the autism spectrum: a twin study. *J Am Acad Child Adolesc Psychiatry.* 2006;45(6):691–9.
155. Ronald A, Happe F, Plomin R. The genetic relationship between individual differences in social and nonsocial behaviours characteristic of autism. *Dev Sci.* 2005;8(5):444–58.
156. Dissanayake C, et al. Behavioural and cognitive phenotypes in idiopathic autism versus autism associated with fragile X syndrome. *J Child Psychol Psychiatry.* 2009;50(3):290–9.
157. Harris SW, et al. Autism profiles of males with fragile X syndrome. *Am J Ment Retard.* 2008;113(6):427–38.
158. Loesch DZ, et al. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. *Neurosci Biobehav Rev.* 2007;31(3):315–26.
159. Muller RA. The study of autism as a distributed disorder. *Ment Retard Dev Disabil Res Rev.* 2007;13(1):85–95.
160. Roberts JE, et al. Social approach and autistic behavior in children with fragile X syndrome. *J Autism Dev Disord.* 2007;37(9):1748–60.